RAPH
Raphael Pharmaceutical Inc.1.4000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
27.48MP/E (TTM)
-Basic EPS (TTM)
-0.07Dividend Yield
0%Recent Filings
10-K
FY2025 results
Raphael Pharmaceutical posted FY2025 results reflecting its clinical-stage status, with no revenue as it advances cannabinoid-based therapies for RA and asthma; a proof-of-concept RA study wrapped in December 2024, paving the way for RaphaWell dietary supplement launch in August 2025. Q4 saw product development completion and a November provisional patent filing on neutrophil-dominant autoimmune treatments, while ongoing Rambam research targets asthma models. No sales or profitability yet. Cash burn persisted on R&D, including $1.4M Research Agreement payments plus $470K supplement (partly outstanding at ~$298K). Liquidity details not disclosed. No guidance provided. Regulatory delays threaten momentum.
10-Q
Q3 FY2025 results
Raphael Pharmaceutical narrowed its Q3 operating loss to $251K, down 21% y/y from $319K, while YTD operating loss fell 11% to $991K from $1,115K, driven by 55% lower R&D at $73K versus prior-year clinical costs at Rambam. G&A rose 13% to $178K on related-party services, yet net loss improved 22% y/y to $255K; financial expense added just $4K. Cash dwindled to $3K amid $256K operating burn, offset by $240K equity raises, with $755K CEO payables and $41K director loan at 12%. Stockholders' deficit hit $1.3M. Cash won't last. Regulatory approvals remain elusive.
10-Q
Q2 FY2025 results
Raphael Pharmaceutical narrowed its six-month operating loss to $740K from $796K a year ago, thanks to R&D expenses dropping 47% to $213K amid scaled-back work with Rambam, though G&A climbed 35% to $527K on professional services. The Q2 operating loss widened to $315K from $249K, driven by a 588% R&D surge to $141K from chief technology officer costs and research pacts. Net loss edged down 6% to $751K YTD, with EPS steady at $0.04 on 19.4M diluted shares, while Q2 hit $0.02. Cash holds at $20K after $240K from stock and warrant issuances offset $239K operating burn; a $41K related-party loan at 12% matures December 2025. No free cash flow disclosed. On July 28, 2025, Raphael amended its Rambam deal, acknowledging a 1,120,623 NIS debt (about $300K) with 80% royalties until repaid by April 2026 from new investments. Funding remains tight.
8-K
RaphaWell RA supplement launch
Raphael Pharmaceutical completed development of its RaphaWell natural supplement for rheumatoid arthritis support on August 7, 2025, following a compliant proof-of-concept trial showing pain levels dropping from 75% to 50% of participants by week 8 and morning stiffness easing from 75% to 41.67%. The 100% plant-based product, with no side effects reported, targets the U.S. wellness market as a standalone dietary supplement, backed by QR-coded study data for credibility. It promises commercial edge in symptom management. Risks include regulatory hurdles and market shifts.
IPO
Sector
Industry
ACB
Aurora Cannabis Inc.
5.53+0.41
CBDL
CBD Life Sciences Inc.
0.00+0.00
CPMD
Cannapharmarx Inc.
0.00-0.00
CRLBF
Cresco Labs Inc.
1.75+0.45
CRON
Cronos Group Inc. Common Share
3.16+0.11
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
GCAN
Greater Cannabis Co Inc.
0.08+0.00
GTBIF
Green Thumb Industries Inc.
9.63+1.23
IMCC
IM Cannabis Corp.
1.73+0.21
INCR
Intercure Ltd.
1.45+0.05